{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"},{"groupId":"OG001","value":"1.1"}]}],"title":"Increase >5%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.6"},{"groupId":"OG001","value":"50.5"}]}],"title":"No change (±5%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.2"},{"groupId":"OG001","value":"27.2"}]}],"title":"Decrease >5-10%"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.7"},{"groupId":"OG001","value":"21.2"}]}],"title":"Decrease >10%"}],"denoms":[{"counts":[{"groupId":"OG000","value":"273"},{"groupId":"OG001","value":"283"}],"units":"Participants"}],"description":"Change in body weight was categorized as an increase of greater than (\\>)5 percent (%), no change (plus or minus \\[±\\]5%), decrease of \\>5-10%, or a decrease of \\>10% from BL to the end of study. Time windows were applied in order to assign visits to weight measurements, and the lowest post-screening value recorded was used for the analysis. The percentage change in weight from screening was summarized over time.","groups":[{"description":"Participants received fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles as follows: cisplatin 80 mg/m\\^2, IV, on Day 1 and EITHER: 5-FU 800 mg/m\\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\\^2, tablets, PO, BID from the evening of Day 1 through the morning of Day 15.","id":"OG000","title":"Fluoropyrimidine/Cisplatin (FP)"},{"description":"Participants received trastuzumab plus fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles (except as noted) as follows: trastuzumab 8 mg/kg, IV, on Day 1 (Cycle 1), followed by 6 mg/kg, IV (Cycles 2 onward, administered until disease progression); cisplatin 80 mg/m\\^2 IV on Day 1; and EITHER 5-FU 800 mg/m\\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\\^2 tablets, PO BID from the evening of Day 1 through the morning of Day 15.","id":"OG001","title":"Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)"}],"paramType":"NUMBER","populationDescription":"FAS. 273 and 283 participants were analyzed in the Fluoropyrimidine, Cisplatin and Trastuzumab, Fluoropyrimidine, Cisplatin groups, respectively.","reportingStatus":"POSTED","timeFrame":"BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis","title":"Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight","type":"SECONDARY","unitOfMeasure":"percentage of participants"}